Serumski bilirubin korelira s adipokinima u serumu kod asimptomatskih odraslih osoba s normalnom i prekomjernom tjelesnom težinom by Ana Petelin et al.
Acta Clin Croat 2020; 59:19-29 Original Scientific Paper
doi: 10.20471/acc.2020.59.01.03
Acta Clin Croat, Vol. 59, No. 1, 2020  19
SERUM BILIRUBIN CORRELATES  
WITH SERUM ADIPOKINES IN NORMAL WEIGHT  
AND OVERWEIGHT ASYMPTOMATIC ADULTS
Ana Petelin1, Mihaela Jurdana1, Zala Jenko Pražnikar1 and Lovro Žiberna2
1Faculty of Health Sciences, University of Primorska, Izola, Slovenia;  
2Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine,  
University of Ljubljana, Ljubljana, Slovenia 
SUMMARY – Overweight and obesity are considered as chronic low-grade inflammation 
 accompanied by imbalanced production of adipokines. The aim of this study was to elucidate the 
 relationship between serum bilirubin, which is an endogenous antioxidant with anti-inflammatory 
activity, and pro- and anti-inflammatory serum adipokines in asymptomatic normal weight and 
 overweight individuals. Healthy men and women aged 25-49 participated in this cross-sectional study. 
All participants underwent fasting serological measurements of adipokines, interleukin-6, tumor 
 necrosis factor alpha (TNF-α), C-reactive protein (CRP), total and direct serum bilirubin, and other 
biochemical parameters. Participants were divided into normal weight and overweight groups. We 
found a significant negative association between total bilirubin and CRP, TNF-α, visfatin and resistin 
values, and a significant positive association between total bilirubin and adiponectin values in both 
normal-weight and overweight groups. Importantly, after adjusting for body mass index, we also 
found a significant negative association between total serum bilirubin levels and both visfatin and 
CRP serum levels. Moreover, visfatin, resistin and CRP were predictors of the total serum bilirubin 
levels.
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Introduction
Imbalance in the production of adipocytokines 
(adipokines) from adipose tissue is involved in various 
pathological states, such as metabolic syndrome, hy-
perlipidemia, hypertension, atherosclerosis and diabe-
tes mellitus, among others1-3. Adipokines determine 
adipose tissue function, fat distribution, fat mass, liver 
function, insulin sensitivity; and importantly, visceral 
fat accumulation also has an impact on adipokine se-
cretion profile4. In addition, adipose tissue via adipo-
kines plays an important role in the regulation of im-
mune response and systemic inflammation. In this 
view, action of adipokines is either pro-inflammatory 
(e.g., leptin, resistin, interleukin-6 (IL-6), tumor ne-
crosis factor alpha (TNF-α)), or anti-inflammatory 
(e.g., adiponectin)5.
It remains a challenge to identify asymptomatic in-
dividuals who are at an increased risk of developing 
metabolic syndrome. Serum bilirubin is a strong en-
dogenous antioxidant with anti-inflammatory proper-
ties6,7. Several epidemiological and large-scale popula-
tion studies have shown that higher serum bilirubin 
levels protect against the development of diabetes 
mellitus, hypertension, coronary artery disease, stroke, 
and cardiovascular diseases (CVD)7-12. Serum bilirubin 
levels were also inversely correlated with the preva-
lence of metabolic syndrome, which is considered as 
a pre-diabetes state9,10. Moreover, bilirubin has been 
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 recently speculated as a potential pre-disease biomark-
er for the development of metabolic syndrome in as-
ymptomatic middle-aged individuals13. In this per-
spective, bilirubin can be considered as surrogate end-
point for cardiovascular or metabolic diseases, espe-
cially if measured longitudinally over time in single 
patient to reflect positive or negative changes due to 
lifestyle modification or therapeutic approaches. This 
consistent pathophysiological evidence combined with 
the epidemiological data opens up the perspective for 
bilirubin to be used as a biomarker for therapeutic in-
terventions.
Overweight and obese individuals have increased 
serum levels of pro-inflammatory adipokines such as 
leptin, TNF-α, IL-6, resistin, and visfatin14. Interest-
ingly, resistin that is released within fat tissue acts on 
adipocytes directly, thus leading to insulin resistance 
independently of body mass index (BMI)15. In contrast 
to other adipokines, serum levels of adiponectin de-
crease in obese subjects16. Furthermore, hypoadiponec-
tinemia is associated with visceral fat accumulation, 
and is also closely linked to higher waist circumfer-
ence, blood pressure, fasting insulin, insulin resistance 
index, total cholesterol, low density lipoprotein (LDL) 
cholesterol, very low density lipoprotein (VLDL) cho-
lesterol, and triacylglycerols17,18. Accordingly, decreased 
serum levels of adiponectin are considered as a new 
hypothesis to explain the pathophysiology of meta-
bolic syndrome19.
Here we proposed the idea that serum adipokines 
and serum bilirubin might have direct correlation al-
ready in the asymptomatic individuals, i.e. in the early 
pre-disease states. The proof of this concept could open 
the perspective of using longitudinal screening of serum 
bilirubin values as a biomarker for cardiovascular and 
metabolic pre-disease states, in which reversible chang-
es with lifestyle modification are still possible. Up to 
date, the role of adipokines in respect to bilirubin is de-
scribed in the literature mainly in studies dealing with 
hepatic diseases. On the other hand, induction of biliru-
bin synthetic enzyme heme oxygenase-1 (HO-1) in 
adipocytes improved adipocyte function and adipose 
remodeling by increasing adiponectin levels20.
In a recent clinical study, serum bilirubin was posi-
tively correlated to adiponectin21. Therefore, the aim of 
our study was to elucidate the relationship between 
serum adipokines and serum bilirubin levels in asymp-
tomatic normal weight and overweight individuals.
Materials and Methods
Study population
In this cross-sectional study, 96 apparently healthy 
participants of Caucasian origin were included. Par-
ticipants were recruited by internet and media adver-
tisement and selected by the following exclusion crite-
ria: (i) having 19≥BMI≥35; (ii) having drug therapy 
for lipid disorders, or taking non-steroidal anti-in-
flammatory drugs (NSAIDs); (iii) having any cardio-
vascular, endocrine, acute or chronic inflammatory dis-
ease, including diabetes mellitus type 2; (iv) being a 
smoker; and (v) not completing the questionnaires, or 
not reporting stable weight over the last three months 
(loss or gain <3% of the subject’s weight was tolerated). 
All volunteers were fully informed on the study proce-
dures, and written informed consent was obtained 
from each subject upon enrolment. The study was con-
ducted with approval from the Slovenian National 
Medical Ethics Committee (No. 56/08/11 bis), and 
the experimental protocol was in accordance with the 
Declaration of Helsinki from 2004.
Measurement of body composition
Subject anthropometric measures, including height, 
weight, waist and hip circumference were performed 
by the protocol previously described13. All participants 
were subjected to the following measurements: (i) 
body weight was recorded to the nearest 0.1 kg, and 
height to the nearest 0.1 cm in standing position using 
a Leicester Height Measure (Invicta Plastics Limited, 
Oadby, England); (ii) waist circumference was mea-
sured midway between the costal edge and iliac crest; 
(iii) calculating BMI; and (iv) body composition anal-
yses (total percentage of body fat (% BF) and trunk fat 
(% TF)) were performed using a body composition 
analyzer (BIA) Tanita BC 418MA (Tanita Corpora-
tion, Arlington Heights, IL, USA). Overweight group 
consisted of all participants that had at least two of 
three following characteristics: (i) BMI ≥25 kg/m2; (ii) 
visceral obesity – waist circumference (≥94 cm (men) 
and ≥80 cm (women); and (iii) % of total fat (≥21.5% 
(men) and ≥32% (women).
Serum measurements
After overnight fast, whole blood samples for dif-
ferent biochemical analyses were collected in the 
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morning into red topped tubes (Becton-Dickinson, 
Rutherford, USA). After whole blood collection, the 
blood was left at room temperature for 20 minutes. 
Then, the clot was removed immediately by centrifu-
gation; the resulting supernatant was transferred into a 
clean polypropylene tube frozen and stored at -20 °C 
until analysis.
Cytokines, including IL-6 and TNF-α, but also 
adipokine visfatin were measured in serum, as previ-
ously described22. Briefly, serum levels of visfatin, IL-6, 
TNF-α and adiponectin were determined in duplicate 
on a microplate reader (Tecan, Männedorf, Switzer-
land) using human ELISA kit for visfatin (BioVision, 
Mountain View, CA, USA), IL-6 and TNF-α (Ther-
mo Fischer Scientific Inc., Rockford, USA), and adi-
ponectin and resistin (BioVendor, Laboratory Medi-
cine Inc., Brno, Czech Republic). Assay sensitivity was 
26 ng/mL for adiponectin and 33 pg/mL for resistin, 
whereas inter-assay and intra-assay coefficient of vari-
ation (CV) was <10% both. In addition, serum con-
centrations of different biochemical parameters were 
analyzed using standard techniques, as previously re-
ported13. To sum up, using Olympus reagents, serum 
concentrations of total and direct bilirubin, standard 
serum blood lipids, including total cholesterol, LDL 
cholesterol, HDL cholesterol and triacylglycerols but 
also serum glucose and CRP were measured on an AU 
680 analyzer (Beckman Coulter, Pasadena, CA, USA). 
In addition, serum insulin levels were analyzed on an 
Abbott Architect 2000 iSR analyzer (Abbott Diag-
nostics, Abbot Park, IL, USA).
Statistics
Descriptive statistics was used to analyze data dis-
tribution and to summarize the data. Non normally 
distributed data (concentrations of bilirubin, adipo-
nectin, visfatin, TNF-α, LDL cholesterol, triacylglyc-
erols, CRP, and insulin) were logarithmically trans-
formed to approximate normal distribution. In general, 
data were expressed as mean ± SD unless otherwise 
stated. To analyze the effect of obesity measures on se-
rum bilirubin, adipokines and inflammatory markers, 
subjects were divided according to obesity measures 
(body fat, BMI, and waist circumference). Indepen-
dent Student’s t-test was used to compare the two 
groups. Spearman’s correlation analyses were used to 
detect relationships between fasting serum concentra-
tions of bilirubin and adipokines or inflammatory 
markers before and after BMI adjustment. Step by 
step regression analysis was used to explore the predic-
tors of fasting serum concentrations of total bilirubin 
(dependent variable). Independent variables were adi-
pokines and cytokines. Moreover, hierarchical multiple 
regression analysis was performed to examine the ef-
fects of studied adipokines on serum bilirubin levels. 
First, general parameters (age and gender) were en-
tered as control variables (step 1), followed by indica-
tors of obesity (waist to hip ratio and body fat mass) 
(step 2). Then, some other possible confounders such 
as fasting glucose, insulin, triacylglycerols and total 
cholesterol were entered (step 3), followed by adipo-
kines and inflammatory markers (step 4). For all statis-
tical analyses, the IBM SPSS version 19.0 (SPSS Inc., 
Chicago, IL, USA) was used. The level of statistically 
significant difference between the tested parameters 
was set at p<0.05.
Results
Baseline anthropometric and biochemical  
characteristics
Some of the previously described anthropometric 
and biochemical data on the two study groups, i.e. 
 normal weight (16 male and 32 female participants) 
and overweight (16 male and 32 female participants) 
are shown in Tables 1 and 2. Participants in the two 
groups differed in all obesity measures, including BMI, 
waist to hip ratio, % BF, and % TF. The metabolic pro-
file of cytokines and adipokines of the two study 
groups is shown in Table 2. Subjects in the overweight 
group had significantly higher levels of fasting insulin, 
blood lipids, including triacylglycerols, total choles-
terol and LDL cholesterol, and lower levels of HDL 
cholesterol and total bilirubin as compared with the 
normal weight group. In the overweight group, circu-
lating levels of CRP, IL-6, visfatin, and TNF-α were 
higher, while adiponectin levels were lower. 
Correlation between serum adipokines  
and bilirubin levels
Bilirubin is present in serum in conjugated (direct 
bilirubin) and unconjugated (indirect bilirubin) forms. 
The sum of both forms results in total bilirubin. Serum 
bilirubin levels, i.e. total and direct bilirubin, were 
higher in the normal weight participants in compari-
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Table 1. Anthropometric and biochemical parameters of normal weight and overweight groups, previously published by 
Jenko-Pražnikar et al.13
Normal weight subjects Overweight subjects p value
Number of participants 48 48 NS
Gender (M/F) 16/32 (33%/67%) 16/32 (33%/67%) NS
Age (years) 37±6 39±6 NS
BMI (kg/m2) 21.9±2.4 29.4±2.7 <0.001
Waist to hip ratio 0.82±0.07 0.88±0.09 <0.001
Body fat (%) 21±6 34±8 <0.001
Trunk fat (%) 19±6 33±6 <0.001
Fasting glucose (mmol/L) 5.0±0.4 5.2±0.4 NS
Fasting insulin (unit) 5.4±1.7 9.2±4.3 <0.001
Triacylglycerols (mmol/L) 0.94±0.50 1.38±0.74 <0.001
Total cholesterol (mmol/L) 5.0±0.9 5.6±1.1 0.011
HDL cholesterol (mmol/L) 1.5±0.3 1.3±0.3 0.001
LDL cholesterol (mmol/L) 3.1±0.7 3.6±1.0 0.004
CRP (mg/L) 0.84±0.86 3.02±3.06 <0.001
Bilirubin-total (µmol/L) 15.4±3.1 13.2±2.8 0.042
Bilirubin-direct (µmol/L) 2.5±0.6 2.1±0.6 0.038
All values are mean ± SD; M = male; F = female; BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein; 
CRP = C-reactive protein; NS = nonsignificant.
Comparisons of biochemical and other characteristics between the two groups were completed with the use of one-factor analysis of vari-
ance with Bonferroni correction. The mean difference was significant at the 0.05 level.







participants 48 48 NS
TNF-α 
(pg/mL) 2.0±1.6 5.2±3.3 <0.001
IL-6 
(pg/mL) 2.8±1.0 3.2±0.9 0.021
Adiponectin 
(µg/mL) 7.0±3.8 4.6±2.7 0.009
Resistin 
(µg/mL) 8.0±2.5 8.2±2.6 ns
Visfatin 
(ng/mL) 2.0±0.6 4.2±0.9 0.002
All values are mean ± SD; IL-6 = interleukin 6; TNF-α = tumor 
necrosis factor alpha; NS = nonsignificant.
Comparisons of biochemical and other characteristics between the 
two groups were completed with the use of one-factor analysis of 
variance with Bonferroni correction. The mean difference was sig-
nificant at the 0.05 level.
Table 3. Spearman correlation coefficients of fasting  
serum levels of total bilirubin with adipokines  
and after adjustment for BMI
Independent 
variable Total bilirubin
Total bilirubin after 
adjustment for BMI
r p r p
CRP -0.33 0.001 -0.33 0.001
TNF-α -0.29 0.018 -0.17 0.251
Visfatin -0.31 0.021 -0.29 0.034
Adiponectin 0.24 0.024 0.14 0.321
Resistin -0.25 0.019 -0.24 0.059
IL-6 0.14 0.151 0.10 0.434
BMI = body mass index; CRP = C-reactive protein; IL-6 = inter-
leukin 6; TNF-α = tumor necrosis factor alpha
son to the overweight participants. Both forms of bili-
rubin correlated in the same manner with the increas-
ing number of metabolic syndrome parameters, as 
published previously13. Associations of total serum 
bilirubin with both serum adipokines and pro-inflam-
matory cytokines are shown in Table 3 and Figure 1. 
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Fig. 1. Correlations between total serum bilirubin levels and serum cytokines and adipokines levels.
(A) Serum adiponectin; (B) serum visfatin; (C) C-reactive protein (CRP); (D) serum interleukin-6 (IL-6); (E) serum 
 tumor necrosis factor alpha (TNF-alpha); (F) serum resistin. Results are presented for male (0) and female (1) participants 
(circles and squares). Pearson’s correlation analysis was performed (N=96).
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We detected a significant negative association between 
total bilirubin and CRP, TNF-α, visfatin and resistin 
values, and a significant positive association between 
total serum bilirubin and adiponectin values (p<0.05 
all) (Table 3), before stratifying subjects on the basis of 
BMI. Importantly, after BMI adjustment, we found a 
significant negative association between total serum 
bilirubin levels and both visfatin (-0.29; p=0.034) and 
CRP (-0.33; p=0.001) serum levels. Due to the known 
relationship between BMI and bilirubin levels, both 
associations were less strong, but still statistically sig-
nificant.
Moreover, Table 4 shows the results of linear re-
gression analysis between the level of the dependent 
variable of serum bilirubin (total and direct) and CRP, 
TNF-α, visfatin, resistin, adiponectin and IL-6. All as-
sociations except for resistin were stronger and more 
significant in males than in females.
Adipokines as predictors of serum bilirubin level
Results of multiple stepwise regression analyses 
with serum bilirubin (total) as a dependent variable in 
male and female subjects are presented in Table 5. Vis-
fatin was strong and gender nonspecific predictor of 
serum bilirubin. Furthermore, CRP was predictor of 
serum bilirubin in male individuals, and resistin in fe-
male subjects.
To further examine the effects of adipokines on se-
rum bilirubin level, we also performed hierarchical 
multiple regression analysis, as shown in Table 6. The 
hierarchical multiple regression revealed that at stage 
one, general parameters, e.g., age and gender, contrib-
uted to the regression model and accounted for 13% of 
the variation in serum levels of bilirubin. Introducing 
obesity parameters in stage two of the regression mod-
el (e.g., waist to hip ratio and body fat mass) explained 
additional 4% of the variation in serum level of biliru-
bin. In addition, the results of the regression in step 3 
indicated that four predictors (fasting glucose, insulin, 
triacylglycerols and total cholesterol) explained an ad-
ditional 24% of the variation in serum level of biliru-
bin, and change in R² was significant (p<0.01). Step 4 
was also significant with adipokines and CRP as im-
portant predictors of serum bilirubin level (visfatin 
and CRP significantly contributed to the explained 
variation of serum bilirubin level) and explained 11% 
of the variation of serum bilirubin level. It was found 
that the level of serum bilirubin was significantly pre-
dicted by body fat mass (β=-0.436, p<0.05), slightly 
more as did fasting insulin (β=-0.415, p<0.01), visfatin 
Table 5. Results of multiple stepwise regression analysis 
with serum bilirubin (total) as a dependent variable  




β p β p
CRP -0.53 0.020 -0.22 NS
TNF-α -0.15 ns -0.14 NS
IL-6 0.13 ns -0.08 NS
Adiponectin 0.21 ns 0.22 NS
Visfatin -0.46 0.006 -0.28 0.039
Resistin -0.04 ns -0.35 0.020
CRP = C-reactive protein; IL-6 = interleukin 6; TNF-α = tumor 
necrosis factor alpha; NS = nonsignificant
Variables included in the model were CRP, TNF-α, IL-6, adipo-
nectin, resistin and visfatin. Only significant p values are shown in 
multivariate analysis (p<0.05).
Table 4. Results of linear regression analysis (by gender) between serum bilirubin (total and direct) level 
and other variables
Independent variable Total bilirubin Direct bilirubin
r (M/F) p (M/F) r (M/F) p (M/F)
CRP -0.71/-0.28 <0.0001/0.047 -0.62/-0.31 <0.0001/0.046
TNF-α -0.30/-0.25 0.016/0.032 -0.24/-0.23 0.047/0.048
IL-6 0.28/-0.13 0.131/0.323 0.26/-0.11 0.157/0.420
Adiponectin 0.33/0.23 0.011/0.029 0.36/0.25 0.010/0.021
Visfatin -0.42/-0.31 0.012/0.018 -0.30/-0.29 0.019/0.023
Resistin -0.15/-0.37 0.167/0.004 -0.13/-0.28 0.276/0.032
M = male; F = female; CRP = C-reactive protein; IL-6 = interleukin 6; TNF-α = tumor necrosis factor alpha
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(β=-0.321, p<0.05), serum triacylglycerols (β=-0.301, 
p<0.05) and CRP (β=-0.284, p<0.05). Together, the 
adjusted R² value was 0.52. This indicated that 52% of 
the variance in serum level of bilirubin was explained 
by the proposed model.
Discussion
In this study, we demonstrated for the first time 
that total serum bilirubin levels in overweight and 
normal weight middle-aged asymptomatic subjects 
were negatively associated with some proinflammatory 
adipokines, such as visfatin and resistin, and inflam-
matory cytokines such as TNF-α, IL-6 and CRP, 
whereas serum bilirubin was positively associated with 
anti-inflammatory adiponectin. Moreover, serum lev-
els of CRP, visfatin, and resistin were strong predictors 
of serum bilirubin levels.
Bilirubin in normal concentration is a potent en-
dogenous antioxidant and anti-inflammatory agent in 
serum, which can neutralize free radicals, prevent per-
oxidation of lipids, and decrease oxidative stress23. In-
deed, in our study, we observed an inverse relationship 
between serum bilirubin levels and pro-inflammatory 
cytokines (TNF-α, IL-6) and CRP, thereby confirm-
ing the anti-inflammatory activity of bilirubin, as pre-
viously described24. Our data are in agreement with 
other studies, describing that total bilirubin was in-
versely correlated with CRP in overweight sub-
jects8,12,25. In addition, in our study, CRP level was a 
predictor of serum bilirubin in male individuals. On 
the other hand, weight loss is associated with a rapid 
increase in total bilirubin levels and antioxidant capac-
ity12,25.
We showed that adiponectin, which is an anti-in-
flammatory adipokine, was positively correlated with 
serum bilirubin levels in asymptomatic middle-aged 
individuals. Previously, positive correlation of adipo-
nectin with serum bilirubin was described in non-dia-
betic men; however, in comparison to our study, those 
subjects were older, some were symptomatic (hyper-
tension, microalbuminuria), and/or smokers, which all 
can affect serum bilirubin levels21. Many other studies 
described this correlation in patients with liver cell in-
jury, e.g., cirrhosis and cholestasis26. It is important to 
notice that both serum bilirubin6 and serum adiponec-
tin5,27 have beneficial effects in a variety of CVD. 
Moreover, both show negative correlation with obesity 
and BMI5,9.
The physiology of bilirubin and adiponectin also 
combines in the heme oxygenase-adiponectin axis re-
sponse. Heme oxygenase-1 system is involved in en-
hancing adiponectin synthesis and release28. Patho-
logic conditions such as oxidative stress and inflamma-
tion up-regulate the level of inducible heme oxygenase 
(HO-1), thereby increasing total bilirubin levels29. 
Overexpression of HO-1 resulted in a marked increase 
in adiponectin with a corresponding decrease in the 
levels of inflammatory cytokines TNF-α, IL-1β and 
IL-6 in animal models of obesity20,30. Indeed, we ob-
served a correlation between TNF-α and serum biliru-
bin, but there was no correlation with IL-6. Moreover, 
HO-1 induction alters the physical appearance of adi-
pocytes, i.e. from few large to many smaller adipo-
Table 6. Results of hierarchical multiple regression 
analysis for variables predicting serum bilirubin levels#
Dependent variable  
– bilirubin
Predictor β F ΔR2
Step 1: 4.40 0.13*
Age -0.243
Gender -0.216
Step 2: 2.82 0.04*
Waist to hip ratio -0.203
Body fat mass -0.436*














# BMI = body mass index; CRP = C-reactive protein; IL-6 = inter-
leukin 6; TNF-α = tumor necrosis factor alpha; *p<0.05, and 
**p<0.01.
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cytes31. These modified adipocytes led to increases in 
anti-inflammatory AMPK, PPARγ, and adiponectin, 
whereas on the other hand, they decreased the produc-
tion of inflammatory cytokines such as TNF-α and 
IL-631. Furthermore, HO-1 induction was found to be 
beneficial in obesity by inhibiting adipogenesis, i.e. 
preventing the formation of adipose tissue from mes-
enchymal stem cells32. Indeed, diabetic patients have 
reduced HO-1 responses to chronic inflammation and 
oxidative stress, and thus consequently lower serum 
bilirubin and adiponectin levels33.
Herewith we report for the first time a strong neg-
ative association between serum visfatin and bilirubin 
levels. In addition, we found higher serum visfatin lev-
els in overweight subjects in comparison to the normal 
weight ones, which is in agreement with previous 
studies22,34. Increased serum visfatin levels are associ-
ated with the obesity-related morbidities35, higher 
presence of coronary artery disease36, and higher risk of 
acute myocardial infarction37. Visfatin was positively 
associated with insulin resistance, and thus suggested 
as a biomarker for predicting obesity, diabetes status, 
insulin resistance, metabolic syndrome and CVDs34. In 
previous studies, increased visfatin levels and increased 
bilirubin levels have been reported in patients with 
liver diseases, e.g., chronic viral hepatitis38. Indeed, 
obese individuals with healthy liver function can have 
increased visfatin levels similar to the patients with 
non-alcoholic fatty liver disease39. Thus, negative cor-
relation between serum bilirubin and visfatin applies 
only to the individuals with no liver disease.
A major limitation of our cross-sectional study was 
a small number of subjects enrolled. Thus, a prospec-
tive study involving a larger number of subjects is nec-
essary to confirm the correlation between serum bili-
rubin and studied adipokines, and to further investi-
gate low serum bilirubin levels as a cardiovascular risk 
factor in overweight subjects. Secondly, our study as-
sumed that total bilirubin levels correlated with free 
bilirubin, which is the unconjugated and unbound 
bilirubin40. It is the bioactive form, but it is not rou-
tinely measured in clinical settings; however, in healthy 
adults, its concentration is around 10 nM41. To better 
elucidate the bilirubin mechanisms of actions on adi-
pocytes, free bilirubin values should be employed in 
future studies.
There is only scarce evidence for bilirubin effects on 
adipocytes. However, bilirubin can act as: (i) direct 
radical scavenger of reactive oxygen species (ROS) and 
nitrogen species since reduced oxidative stress in adi-
pocytes decreases the activation of the intracellular 
ASK1-MEK4-JNK signaling pathway that is crucial 
in insulin resistance42; (ii) inhibitor of NAPDH oxi-
dase, which is the most important source of intra-
cellular adipocyte ROS production42; and (iii) acti- 
vator of peroxisome-proliferator-activated receptor α 
(PPARa)43. Another possible explanation could be the 
anti-inflammatory effects of bilirubin on activated 
macrophages in hypertrophic visceral adipose tissue, 
which also express high levels of NADPH oxidase44.
Overall, serum bilirubin has been previously shown 
to be decreased in asymptomatic individuals before the 
onset of metabolic syndrome, on the basis of correlation 
with body weight, fat level, insulin resistance, LDL, 
HDL, triacylglycerols, CRP and physical activity. Here 
we further support this view by presenting that altered 
adipokine levels decrease in anti-inflammatory adipo-
nectin and increase in pro-inflammatory visfatin are 
also correlated with lower serum bilirubin levels. Impor-
tantly, this study was conducted in asymptomatic, non-
smoking, middle-aged individuals with stable body 
weight, who are the key population for CVD preven-
tion. This study opens the perspective of measuring adi-
pose tissue dysfunction by serum biomarkers such as 
adipokines and bilirubin, and studying their role in the 
early pathogenesis of metabolic syndrome.
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Sažetak
SERUMSKI BILIRUBIN KORELIRA S ADIPOKINIMA U SERUMU  
KOD ASIMPTOMATSKIH ODRASLIH OSOBA  
S NORMALNOM I PREKOMJERNOM TJELESNOM TEŽINOM
A. Petelin, M. Jurdana, Z. Jenko Pražnikar i L. Žiberna
Prekomjerna tjelesna težina i pretilost smatraju se kroničnom upalom niskog stupnja praćenom neuravnoteženom proiz-
vodnjom adipokina. Cilj istraživačkog rada bio je razjasniti odnos između serumskog bilirubina, koji je endogeni antioksidans 
s protuupalnom aktivnošću, i pro- i protuupalnih serumskih adipokina kod asimptomatskih pojedinaca s normalnom i poje-
dinaca s prekomjernom tjelesnom težinom. U ovoj presječnoj studiji sudjelovali su zdravi muškarci i žene u dobi od 25 do 49 
godina. Mjereni su biokemijski parametri, adipokini, interleukin-6 (IL-6), faktor tumorske nekroze (TNF-α), C-reaktivni 
protein (CRP), ukupni i direktni serumski bilirubin. Sudionici su bili podijeljeni u dvije skupine: osobe s normalnom i osobe 
s prekomjernom tjelesnom težinom. Pronašli smo statistički značajnu negativnu povezanost između ukupnog bilirubina i 
vrijednosti CRP, TNF-α, visfatina i rezistina te statistički značajnu pozitivnu povezanost između ukupnog bilirubina i adi-
ponektina u objema skupinama. Dodatno, nakon prilagodbe indeksa tjelesne mase našli smo značajnu negativnu povezanost 
između ukupnog bilirubina te visfatina i CRP. Multivarijatna logistička regresijska analiza je pokazala da su visfatin, rezistin 
i CRP prediktori ukupnog bilirubina. 
Ključne riječi: Adipokini; Bilirubin; C-reaktivni protein; Prekomjerna težina; Pretilost; Presječno istraživanje
